Antiplatelet Therapy in ACS and A-Fib
Editor(s): Serebruany V.L. (Towson, Md.)
Atar D. (Oslo)
Publication year: 2012
|Buy this book|
|Digital Version:||CHF 142.00, EUR 133.00, USD 167.00|
|Print Version:||CHF 142.00, EUR 133.00, USD 167.00|
|The final prices may differ from the prices shown due to specifics of VAT rules, postage and handling.|
|Order this title|
You already have online access to this title. If you would like to buy a personal digital or print copy, please click here.
Advances in Cardiology , Vol. 47
Editor(s): Borer J.S. (New York, N.Y.)
VI + 170 p., 20 fig., 6 in color, 16 tab., hard cover, 2012
With this in mind, some of the issues outlined in this book are new insights in genetic testing and modification of individualized antiplatelet therapy based on rapid bedside platelet analyzers. Most importantly, the current update of pros and cons of novel antiplatelet agents such as prasugrel and ticagrelor are provided in detail. Conventional antiplatelet strategies with aspirin and clopidogrel are also discussed. Special attention is devoted to experimental antiplatelet agents like PAR-1 thrombin receptor antagonists or aptamers.
The ability to focus on different diseases beyond ACS, including heart failure and atrial fibrillation, distinguishes this publication. Each chapter was written by top experts in the field and scientists with the utmost authority and expertise to provide cardiologists, internists, and clinical pharmacologists with the latest updates.